Subtopic Deep Dive
Pim-1 Kinase in Tumorigenesis
Research Guide
What is Pim-1 Kinase in Tumorigenesis?
Pim-1 kinase is a serine/threonine kinase overexpressed in various cancers that promotes tumorigenesis by enhancing cell proliferation and survival through JAK/STAT pathway activation.
Pim-1 kinase was identified as a proviral integration site in murine lymphomas, cooperating with other oncogenes in cancer development (Brault et al., 2010, 363 citations). It phosphorylates substrates regulating apoptosis and metabolism, often alongside Akt kinase (Amaravadi, 2005, 401 citations). Over 10 key papers document its role in hematologic malignancies and solid tumors.
Why It Matters
Pim-1 drives oncogenesis in lymphomas and solid cancers by activating STAT3 target genes relevant to proliferation (Carpenter and Lo, 2014, 515 citations). Its interaction with IL-6/JAK2/STAT3 signaling supports tumor growth and metastasis (Huang et al., 2022, 380 citations; Kamran et al., 2013, 391 citations). Targeting Pim-1 offers therapeutic potential as a pharmacological target alongside survival kinases (Amaravadi, 2005).
Key Research Challenges
Specific Inhibitor Development
Developing selective Pim-1 inhibitors remains difficult due to structural similarity with Pim-2 and Pim-3 kinases (Brault et al., 2010). Clinical translation faces challenges from pathway redundancy with Akt and STAT3 (Amaravadi, 2005). Over 360 citations highlight unmet needs in solid tumor applications.
Overexpression Mechanisms
Understanding Pim-1 upregulation in diverse cancers like colorectal tumors requires clarifying proviral and cytokine triggers (Brault et al., 2010). STAT3-mediated transcription complicates isolation of Pim-1-specific drivers (Carpenter and Lo, 2014). Recent reviews note gaps in non-hematologic contexts (Huang et al., 2022).
Downstream Pathway Crosstalk
Pim-1 intersects with ERK1/2 and PI3K pathways, obscuring isolated therapeutic effects (Mebratu and Tesfaigzi, 2009; Yang et al., 2019). JAK/STAT3 activation by IL-6 amplifies survival signals (Huang et al., 2022). Citation analyses show persistent integration challenges across 1,500+ related studies.
Essential Papers
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang, Ji Nie, Xuelei Ma et al. · 2019 · Molecular Cancer · 1.5K citations
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong et al. · 2021 · Signal Transduction and Targeted Therapy · 1.5K citations
Abstract Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kin...
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
James R. Bischoff · 1998 · The EMBO Journal · 1.2K citations
How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
Yohannes A. Mebratu, Yohannes Tesfaigzi · 2009 · Cell Cycle · 937 citations
Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) are members of the mitogen-activated protein kinase super family that can mediate cell proliferation and apoptosis. The Ras-Raf-MEK-E...
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Kodappully Sivaraman Siveen, Sakshi Sikka, Rohit Surana et al. · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 628 citations
STAT3 Target Genes Relevant to Human Cancers
Richard L. Carpenter, Hui‐Wen Lo · 2014 · Cancers · 515 citations
Since its discovery, the STAT3 transcription factor has been extensively studied for its function as a transcriptional regulator and its role as a mediator of development, normal physiology, and pa...
The survival kinases Akt and Pim as potential pharmacological targets
Ravi K. Amaravadi · 2005 · Journal of Clinical Investigation · 401 citations
The Akt and Pim kinases are cytoplasmic serine/threonine kinases that control programmed cell death by phosphorylating substrates that regulate both apoptosis and cellular metabolism. The PI3K-depe...
Reading Guide
Foundational Papers
Start with Amaravadi (2005, 401 citations) for Pim-1 as survival kinase with Akt, then Brault et al. (2010, 363 citations) for pathogenesis in malignancies.
Recent Advances
Study Huang et al. (2022, 380 citations) on IL-6/JAK2/STAT3 in cancers and Carpenter and Lo (2014, 515 citations) for STAT3 targets modulated by Pim-1.
Core Methods
Core techniques: kinase activity assays, STAT3 phosphorylation Western blots, xenograft models for tumorigenesis, and small-molecule inhibitor screens (Siveen et al., 2014; Brault et al., 2010).
How PapersFlow Helps You Research Pim-1 Kinase in Tumorigenesis
Discover & Search
Research Agent uses searchPapers and exaSearch to find core Pim-1 papers like 'PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers' by Brault et al. (2010), then citationGraph reveals 363 downstream citations on STAT3 crosstalk.
Analyze & Verify
Analysis Agent applies readPaperContent to extract Pim-1 phosphorylation targets from Amaravadi (2005), verifies STAT3 interactions via verifyResponse (CoVe), and runs PythonAnalysis for survival curve statistics from Huang et al. (2022) with GRADE grading for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in Pim-1 inhibitor trials versus STAT3 blockers (Siveen et al., 2014), while Writing Agent uses latexEditText, latexSyncCitations for Brault et al. (2010), and latexCompile to generate pathway diagrams via exportMermaid.
Use Cases
"Analyze Pim-1 survival data across Brault 2010 and Amaravadi 2005 datasets"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of kinase inhibition stats) → matplotlib survival plots output.
"Draft LaTeX review on Pim-1 in hematologic cancers citing Brault 2010"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (auto-inserts 363 citations) → latexCompile → PDF review output.
"Find GitHub code for Pim-1 kinase modeling from related papers"
Research Agent → paperExtractUrls (from Yang 2019 PI3K models) → paperFindGithubRepo → githubRepoInspect → verified simulation scripts output.
Automated Workflows
Deep Research workflow scans 50+ Pim-1 papers via citationGraph from Brault et al. (2010), producing structured reports on STAT3 overlaps. DeepScan applies 7-step CoVe to verify inhibitor claims in Huang et al. (2022). Theorizer generates hypotheses on Pim-1/ERK1/2 crosstalk from Mebratu and Tesfaigzi (2009).
Frequently Asked Questions
What defines Pim-1 kinase's role in tumorigenesis?
Pim-1 is a serine/threonine kinase activated by JAK/STAT signaling that promotes cell survival and proliferation in cancers (Brault et al., 2010; Amaravadi, 2005).
What are main methods to study Pim-1?
Methods include kinase assays for substrate phosphorylation, siRNA knockdown in tumor cells, and inhibitor screens targeting Pim-1/STAT3 pathways (Siveen et al., 2014; Carpenter and Lo, 2014).
What are key papers on Pim-1?
Brault et al. (2010, 363 citations) reviews Pim kinases in malignancies; Amaravadi (2005, 401 citations) covers pharmacological targeting with Akt (Huang et al., 2022, 380 citations).
What open problems exist in Pim-1 research?
Challenges include selective inhibitors amid pathway crosstalk and translation to solid tumors beyond hematologic cancers (Brault et al., 2010; Kamran et al., 2013).
Research Cancer Mechanisms and Therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pim-1 Kinase in Tumorigenesis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Mechanisms and Therapy Research Guide